Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

In the complex landscape of chronic health conditions, living with HIV while recovering from a stroke presents a unique set ...

The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

The national HIV prevalence was 16. 3% among adults aged 15 years and older, translating to an estimated 7. 4 million adults ...

Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for people like Anna Engomba, the arrival of new, life-saving medication cannot ...

The drug has been approved in Europe and the US as a treatment for HIV/AIDS but does not yet have regulatory approval anywhere in the world as an HIV prevention drug. Once approved, producing enough ...